Gossamer Bio and Chiesi Group collaborate to develop seralutinib for high blood pressure indications, with $326M potential milestones.
Gossamer Bio and Italian drugmaker Chiesi Group have entered a collaboration to develop and commercialize seralutinib for multiple indications related to high blood pressure. This includes pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Gossamer is set to receive a $160M development reimbursement, and could receive up to $146M in regulatory milestones and $180M in sales milestones.
May 06, 2024
3 Articles